How Mounjaro and Compounded Tirzepatide work — mechanism comparison
Mounjaro (tirzepatide) and Compounded Tirzepatide (tirzepatide (compounded)) belong to overlapping but distinct drug classes. Both work via the incretin (gut-hormone) pathway, but they have different molecular targets:
- Mounjaro (tirzepatide) — GLP-1 receptor agonist
- Compounded Tirzepatide (tirzepatide (compounded)) — GLP-1 receptor agonist
This mechanistic difference matters because it determines: efficacy (how much weight loss / blood-sugar control you can expect), side-effect profile, dosing schedule, and which patients may benefit most. Read more in our Mounjaro mechanism guide and Compounded Tirzepatide mechanism guide.
Efficacy head-to-head
Neither Mounjaro nor Compounded Tirzepatide has a weight-loss trial of its own that we can quote, so this comparison does not rank them on weight loss.
Side-by-side radar: Mounjaro vs Compounded Tirzepatide
Editorial scoring across 5 dimensions, overlaid. Higher area = better overall fit.
| Axis | Mounjaro | Compounded Tirzepatide |
|---|---|---|
| Efficacy | 10 | 10 |
| Convenience | 9 | 9 |
| Affordability | 5 | 5 |
| Tolerance | 6 | 6 |
| Evidence | 6 | 6 |
Higher score = better on that axis. Editorial scoring; not a substitute for prescriber judgment.
Side effects compared
Both drugs share the GLP-1 class side-effect profile — primarily gastrointestinal (nausea, diarrhea, constipation, vomiting) in early treatment, fading as the body adapts. Both carry the FDA boxed warning for thyroid C-cell tumors and contraindications for personal/family history of medullary thyroid carcinoma.
Side-effect rate comparator
Trial-derived adverse-event rates with placebo delta. Sourced from FDA-approved labels for each drug. Most sources omit placebo rates entirely.
| Adverse event | Mounjaro | Compounded Tirzepatide |
|---|---|---|
| Nausea | 18%(placebo 4%) +14.0 pp vs placebo | 28%(placebo 8%) +20.0 pp vs placebo |
| Diarrhea | 17%(placebo 9%) +8.0 pp vs placebo | 23%(placebo 8%) +15.0 pp vs placebo |
| Vomiting | 9%(placebo 2%) +7.0 pp vs placebo | 13%(placebo 2%) +11.0 pp vs placebo |
| Decreased appetite | 11%(placebo 1%) +10.0 pp vs placebo | — |
| Constipation | 7%(placebo 1%) +6.0 pp vs placebo | 11%(placebo 5%) +6.0 pp vs placebo |
| Dyspepsia | 5%(placebo 3%) +2.0 pp vs placebo | 10%(placebo 4%) +6.0 pp vs placebo |
| Abdominal pain | 5%(placebo 4%) +1.0 pp vs placebo | 10%(placebo 5%) +5.0 pp vs placebo |
| Injection-site reactions | — | 8%(placebo 2%) +6.0 pp vs placebo |
| Fatigue | — | 7%(placebo 3%) +4.0 pp vs placebo |
Patients who tolerate one GLP-1 well often (but not always) tolerate another. Switching between class members typically requires re-titration regardless of prior tolerability. See full side-effect breakdowns for Mounjaro and Compounded Tirzepatide.
Dosing schedule comparison
Both medications use step-up titration to minimize side effects, but the schedule details differ:
Mounjaro
- Weeks 1–4: 2.5 mg/week
- Weeks 5–8: 5 mg/week
- Weeks 9–12: 7.5 mg/week
- Weeks 13–16: 10 mg/week
- Weeks 17–20: 12.5 mg/week
- Week 21+: 15 mg/week
Compounded Tirzepatide
- Week 1–4: 2.5 mg
- Week 5–8: 5 mg
- Week 9+: 7.5–15 mg
- Maintenance: Up to 15 mg
See full titration guides for Mounjaro dosing and Compounded Tirzepatide dosing.
Cost comparison
Cost differences between Mounjaro and Compounded Tirzepatide depend on insurance coverage, manufacturer savings programs, and partner-network pricing — not just retail price.
- Average retail price (Mounjaro): $1069/month
- Average retail price (Compounded Tirzepatide): $299/month
- Mounjaro savings card: as low as $25/month for eligible commercial-insured
- Compounded Tirzepatide savings card: no standing savings card
For most patients, the actual out-of-pocket cost is driven by: (1) what your insurance formulary tier places Mounjaro vs Compounded Tirzepatide, (2) whether you qualify for manufacturer savings cards (commercial insurance only), and (3) telehealth partner network availability. Full cost breakdowns: Mounjaro cost guide · Compounded Tirzepatide cost guide.
Which one to choose — decision factors
There's no single «better» drug — the right choice depends on individual circumstances. The key decision factors:
Choose Mounjaro if…
- Your insurance covers it but not Compounded Tirzepatide
- Your prescriber has more experience with it
- You're commercially insured and want maximum savings-card benefit
Choose Compounded Tirzepatide if…
- Your insurance covers it but not Mounjaro
- Your prescriber has more experience with it
Switching from Mounjaro to Compounded Tirzepatide (or vice versa)
Switching between Mounjaro and Compounded Tirzepatide (different active ingredients) typically requires restarting titration from the lowest doseof the new drug. Different molecules have different potencies — your tolerated dose of one doesn't map directly to the other. Plan for:
- Return of titration-period side effects (nausea, GI) for 2-4 weeks on restart
- Possibly temporary weight regain during the transition
- Fresh insurance prior-authorization (different drug = new PA)
- 2-4 weeks for the new drug to reach steady-state plasma levels
FAQ — Mounjaro vs Compounded Tirzepatide
Are Mounjaro and Compounded Tirzepatide the same drug?
No — they contain different active ingredients (tirzepatide and tirzepatide (compounded)). They belong to similar drug classes (GLP-1 family) but work via slightly different molecular targets.
Which is more effective for weight loss, Mounjaro or Compounded Tirzepatide?
Neither Mounjaro nor Compounded Tirzepatide has a weight-loss trial of its own that we can quote, so they cannot be ranked on weight loss. See each drug's page for what its label approves it for.
Can I take Mounjaro and Compounded Tirzepatide together?
No. Combining two GLP-1 receptor agonists provides no added benefit and dramatically increases side-effect risk. Standard practice is to switch between them, not combine them.
Which has fewer side effects, Mounjaro or Compounded Tirzepatide?
Both mostly cause stomach side effects such as nausea and diarrhea, which tend to ease with time. We do not hold comparable placebo-controlled rates for both, so we do not rank them on side effects.
Will my insurance cover Mounjaro but not Compounded Tirzepatide?
Often the coverage differs. Insurance formularies are negotiated separately per drug — Mounjaro may be on Tier 2 of your plan while Compounded Tirzepatide is Tier 4 or excluded. Check your formulary before assuming both are equally accessible.
Editorial comparison based on FDA prescribing information and published clinical data. Not a substitute for prescriber consultation. Full medical disclaimer.